Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14540532 | 0.86 | HSD17B1 (0.41) | MEN1ALDH1A1GLAMAPTHPGD | |
| SCHEMBL27953539 | 0.82 | CYP2A6 (0.54) | MEN1ALDH1A1GLAMAPTHPGD | |
| SCHEMBL10332066 | 0.82 | CYP2E1 (0.42) | MEN1ALDH1A1KMT2ACYP2A6HSD17B1 | |
| SCHEMBL19531540 | 0.80 | CYP2A6 (0.66) | CYP2A6HSD17B1HSD17B2CYP2E1CYP3A4 | |
| SCHEMBL1160546 | 0.80 | ALDH1A1 (0.52) | MEN1ALDH1A1GLAMAPTHPGD | |
| SCHEMBL28280412 | 0.80 | ALDH1A1 (0.52) | MEN1ALDH1A1GLAMAPTHPGD | |
| SCHEMBL20746305 | 0.79 | CYP2A6 (0.47) | MEN1ALDH1A1GLAMAPTHPGD | |
| SCHEMBL71397 | 0.79 | CYP2A6 (0.65) | MEN1ALDH1A1GLAMAPTHPGD | |
| SCHEMBL13197660 | 0.78 | CYP3A4 (0.40) | CYP2A6DPP4HSD17B1HSD17B2CYP2E1 | |
| SCHEMBL14003448 | 0.78 | CYP3A4 (0.40) | CYP2A6DPP4HSD17B1HSD17B2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107033095-B | The Oxazolidinone derivative of the structure of hydrazone containing piperazine | 沈阳红旗制药有限公司 | 2019-05-07 | — | — | CN | disclosed |
| CN-107033095-A | The Jie Gou oxazolidinone compounds of hydrazone containing piperazine | 沈阳红旗制药有限公司 | 2017-08-11 | — | — | CN | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2064193-A1 | HETEROCYCLIC GPR40 MODULATORS | Amgen, Inc (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-1993003719-A1 | ARYLALKYLETHER AND ARYLALKYLTHIOETHER INHIBITORS OF LIPOXYGENASE ENZYME ACTIVITY | ABBOTT LABORATORIES (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5183818-A | Also for inhibiting leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1993-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | MEN1 2521/4885ALDH1A1 1814/4885GLA 2188/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | MEN1 2521/4885ALDH1A1 1814/4885GLA 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.